Sign in
CompletedPhase 2/3

Therapeutic Photobiomodulation and Tretament of Spasticity

Key facts

Who runs it
University of Nove de Julho
Where
Brazil1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
12 people enrolled
Started
15 Aug 2023
Ended
31 Dec 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Photobiomodulation
  • Institution's Standard Physiotherapy
  • Photobiomodulation Placebo
Record updated
1 May 2026

Who can take part

Age
2 years to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Patients with diagnosis of spastic cerebral palsy affecting inferior limbs from any etiology
  • Cerebral palsy duration at least 03 months
  • Patients ongoing physiotherapy treatment at University

Who cannot take part

  • Patients using topical photosensitizing medications or creams
  • Patients who present acute clinical conditions with potential for increase spasticity such as acute fractures, skin ulcers, acute infections
  • Patients with severe gastroesophageal reflux disease
  • Patients with another type of movement or tone disorder
  • Patients with a history of photosensitivity to photonic or light therapy
  • Patients with fixed anatomical deformities of the ankle that do not allow ankle joint movement of at least 90 degrees of amplitude
  • Patients with malnutrition
  • Patients who have exposed tumors in the area to be irradiated
  • Patients who have undiagnosed lesions in the treatment region

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Cerebral palsy is a non-progressive, permanent syndrome that occurs in childhood and is accompanied by motor, tônus and posture disorders. Its etiology is related to an insult or damage to the central nervous system in maturation. Approximately 80% of cerebral palsy course with spasticity, which, when left untreated, will generate pain and functional, anatomical and structural changes, with a negative impact. Photobiomodulation therapy has biological effects of tissue regeneration, muscle relaxation, vasodilation, reduction of the inflammatory process and relief of pain symptoms already described in the literature, in addition to being feasible, practical, safe, without side effects, painless and non-invasive.This study is a blind, randomized and controlled clinical trial that will evaluate the effect of photobiomodulation in reducing gastrocnemius muscle spasticity in children aged 2 to 18 years, diagnosed with spastic cerebral palsy of lower limbs of any etiology for at least 03 months and randomized into two groups: application of Low Intensity LED Therapy in the medial and right lateral gastrocnemius muscles (device power of 100mW, wavelength of 850nm, energy of 3J/cm2/point, once a week, making 08 therapeutic days during 02 months) or placebo group Low-Intensity LED Therapy (same device turned off). Both groups will also receive the standard treatment for spasticity. To assess the response to therapy, the outcomes evaluated will be the modified Ashworth Scale, the Mobility Domain of Pediatric evaluation of disability inventory, the Gross Motor Function Classification System scale and passive and active range of motion of the ankle analyzed at the pré and post each therapeutic session and in the pre and post therapeutic period of 08 sessions.

The 2 groups in the trial

  • Photobiomodulation (PBM) Treatment GroupTreatment being tested

    Photobiomodulation therapy sessions will be carried out in the physiotherapy environment on the University, once a week, for 08 consecutive weeks in the same day of the institution's standard physiotherapy session that the patient already uses regularly (not linked to the study). will be transcutaneously, punctual application of the LED in the medial and lateral gastrocnemius muscles of the right lower limb, in contact mode, 3J/cm2, with a 850nm wavelenght (01 point per gastroc, muscle). All patients will received the PBM protocol + the standard physiotherapy rehabilitation treatment of the institute not linked to the study, and which the patient already uses regularly.

    Treatment: Photobiomodulation and Institution's Standard Physiotherapy

  • Photobiomodulation (PBM) Placebo GroupPlacebo, for comparison

    PBM placebo therapy sessions will be carried out with the same characteristics of PBM treatment Group but with device turned off. All patients will received also the standard physiotherapy rehabilitation treatment of the institute not linked to the study, and which the patient already uses regularly.

    Treatment: Institution's Standard Physiotherapy and Photobiomodulation Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Photobiomodulation in the Treatment of Spasticity in Children With Cerebral Palsy. A Controlled, Randomized, Blind Study
Record updated
1 May 2026